Company intelligence / Profile preview

Pixar

Salem, Massachusetts, USA

Ownership: Private
Development stage: Other

Overview

PixarBio was a biotechnology company focused on developing non-opioid pain management and neurological treatments. Its lead product candidate, NeuroRelease, was a sustained-release formulation of carbamazepine designed to treat post-operative pain for up to 14 days. The company also aimed to develop treatments for spinal cord injuries and epilepsy using its proprietary drug delivery platform. However, the company's operations ceased following the conviction of its CEO for securities fraud related to misleading investors about the company's progress and financial health.

Therapeutic areas: Neurology
Modalities: Small moleculeDrug delivery system
Industry: Biotech

Beyond the preview

Go deeper on Pixar.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pixar.

Explore the full profile